AstraZeneca SVP Named Chairman of Innate Pharma Board

From DCAT Value Chain Insights (VCI)

By People On The Move posted 12-28-2016 11:22


Innate Pharma, a clinical-stage biotechnology company based in Marseille, France, has appointed Mondher Mahjoubi, MD, as Chairman of Innate Pharma’s executive board, succeeding Hervé Brailly, PhD, who becomes chairman of the supervisory board. The leadership team and board changes will take effect on December 30th, 2016.

Dr. Mahjoubi is currently senior vice president, therapeutic area head-oncology, global product and portfolio strategy, at AstraZeneca. Dr Mahjoubi brings more than 20 years of experience working in clinical development, marketing, and strategy in Europe and the US for major pharmaceutical companies such as Aventis, Sanofi, Roche-Genentech, and AstraZeneca in the field of oncology.

Dr. Brailly, who co-founded Innate Pharma 17 years ago, joins the supervisory board and will become its chairman, succeeding Gilles Brisson who is stepping down after nine years in that position, and remains on the board. Dr. Philippe Pouletty, the longest serving member of the Board, will resign from the board.

As part of the governance changes, Laure-Hélène Mercier has been appointed as chief financial officer. Ms. Mercier was previously executive vice president, finance, in charge of financial operations and, before that, head of investor relations. Catherine Moukheibir, senior advisor for financial strategy, is leaving the executive board but will maintain her links with the company in an advisory position.

Source: Innate Pharma 


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription